• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

B&L to stay private for 5 years or more

Article

Bausch & Lomb (B&L) bought by Warburg Pincus last October has a long-term growth plan and will not return to the public market any time soon, said Gerry Ostrov, chief executive officer, B&L.

Rochester, NY-Bausch & Lomb (B&L) bought by Warburg Pincus last October has a long-term growth plan and will not return to the public market any time soon, said Gerry Ostrov, chief executive officer, B&L.

"Nobody has given me a specific number, but something like this is probably somewhere north of 5 years. Certainly, we're not talking 1 or 2 years; we are talking 5-plus," Ostrov said in an interview while visiting Britain. "At some time you want to recapture the value, but it's not something I think about when I get up in the morning,

"My personal objective is to get us going at a solid double-digit growth-not immediately, but I think that is an appropriate objective," he said.

According to Ostrov, most divisions of the businesses were little affected by the economic slowdown, but laser eye surgery was suffering, since patients have to pay for procedures costing several thousand dollars out of their own pockets.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.